Abstract Spinal hypotension is a common problem encountered by anesthesiologists when providing spinal anesthesia (SA) for cesarean delivery (CD). Recent research involving use of noninvasive and minimally invasive cardiac output monitoring has improved our understanding of the many pathophysiological mechanisms involved. Crystalloid prehydration (or preload) regimens have failed to have any significant impact on prevention of spinal hypotension, although some benefit of use of either crystalloid or colloid coloading has been demonstrated. Vasopressors remain the mainstay of treatment for both prevention and management of spinal hypotension. Increasing evidence suggests that the vasopressor of choice during SA for CD is phenylephrine (PE), however care should be taken to avoid maternal sinus bradycardia. When PE is administered as an infusion, maternal heart rate and blood pressure should be monitored closely, and any significant decrease in either should be promptly and aggressively treated.
Introduction
Hemodynamic changes during normal pregnancy are characterized by an increase in cardiac output (CO), heart rate (HR), and circulating blood volume and a reduction in systemic vascular resistance (SVR) [1] . Doppler blood flow measurements of maternal CO in the third trimester have revealed alterations in left ventricular diastolic function, associated with an increased HR and dilatation of the left atrium [2] . Among parturients undergoing spinal anesthesia (SA) for cesarean delivery (CD) hemodynamic changes occur as a result of aortocaval compression, the effects of the SA itself, and the usual physiological changes associated with normal pregnancy. It is, therefore, no surprise that, without adequate prophylaxis or treatment, SA is associated with maternal hypotension in 80-83 % of parturients [3, 4 • , 5, 6] .
Substantial research has been directed at finding the optimum way to minimize maternal hypotension during SA for CD. Inadequate hemodynamic control during SA can result in unpleasant symptoms, for example nausea and vomiting, in the mother and can have severe consequences for the fetus by directly compromising uteroplacental blood flow [7 • , 8] . An understanding of the pathophysiological effects of SA on maternal hemodynamics has enabled us to target and correct appropriate physiological variables, and has led to significant advances in the management of spinal hypotension.
This review will focus on the mechanisms involved in spinal hypotension during CD under SA, the use of vasopressor therapy to counteract this effect, and the minimally invasive and non-invasive methods of measuring CO that are currently available.
Pathophysiology of Maternal Hypotension During SA for CD Neuraxial anesthesia has become the anesthetic technique of choice for CD, and has resulted in a reduction in maternal mortality [9, 10 • ] . SA helps to avoid the risk of tracheal intubation, facilitate early bonding between mother and baby, and provide effective neuraxial postoperative analgesia, enabling quicker maternal recovery [11] . It is, however, associated with hypotension in more than 80 % of parturients if not preemptively managed [12] . Spinal hypotension is commonly associated with nausea and vomiting in the mother, and in rare cases can result in cardiovascular collapse, loss of consciousness, or aspiration of gastric contents. Furthermore, prolonged maternal hypotension reduces uteroplacental blood flow, which may cause fetal acidosis, particularly in situations in which there is already fetal compromise [7 • , 8] . Hemodynamic control during CD under SA is therefore very important for the well-being of both the mother and the fetus.
Aortocaval compression predisposes the pregnant mother to decreases in both venous return (VR) and CO. During SA, there is loss of sympathetic tone and a reduction in SVR. This decrease in SVR, further reduces the VR and is associated with a reduction in the maternal CO and a reflex increase in HR. Therefore, both aortocaval compression and SA contribute to the reduction in maternal CO seen during CD [13 • , 14] . Blood pressure (BP) also falls, because mean arterial blood pressure (MAP) depends on both SVR and CO (MAP = CO 9 SVR) [15] .
A variety of measures to improve VR have been tried, for example placing the parturient in the left lateral position to reduce the effects of aortocaval compression, and utilizing different fluid pre and coload regimens, but all have failed to completely eliminate maternal hypotension [16 • ]. Tamilselvan et al. [6] and Teoh and Sia [18] , have demonstrated that increasing CO by fluid preloading before SA does not result in a reduced incidence of spinal hypotension. A randomized controlled trial performed in our institution showed no differences in CO variables or hemodynamic stability between colloid and crystalloid coloading regimens [17 • ].
Much of the recent literature illustrates that a reduction in VR alone cannot be the only contributory factor to spinal hypotension during elective CD. Dyer et al. [19] showed that SA was associated with only modest afterload reduction, little change in CO, and overall adequate hemodynamic stability in a group of 15 severely pre-eclamptic patients. As patients with pre-eclampsia are known to be intravascularly depleted, this would suggest that other factors, apart from a reduction in VR, are involved in the reduction in CO that occurs in normal pregnant patients having SA. A 2009 editorial by Sharwood-Smith and Drummond [15] supports this view. The authors concluded that if VR was the main factor, pre-eclamptic patients would be at major risk of hypotension during spinal anesthesia, because they typically have only an attenuated increase in plasma volume. They further expressed the opinion that in pre-eclampsia the damaged vascular epithelium results in persistent vasoconstriction, and improved hemodynamic stability during spinal anesthesia. In normal pregnancy, however, there is an altered response to endogenous vasopressors, for example angiotensin II, making the parturient prone to vasodilation and hypotension with SA.
After SA for CD there is a decrease in maternal BP, because of falls in both SVR and VR. Traditionally, maternal hemodynamic stability during SA has been assessed by non-invasive measurement of BP and HR. Recent research has used non-invasive and minimally invasive hemodynamic monitoring to study other physiological variables during SA for CD. This has provided more accurate insight into the pathophysiology of spinal hypotension in the healthy parturient. Langesaeter et al. [20] , performed invasive BP and continuous CO monitoring, by use of the LiDCOplus, during elective CD in 80 healthy women, randomized to receive either high-dose or low-dose SA, with either intravenous phenylephrine (PE) or placebo. The onset of SA was associated with a rapid and profound drop in SVR with an initial compensatory increase in CO in all patient groups. This increase in CO presumably resulted from an increase in HR, because no significant changes in SV were seen. Dyer et al. used invasive BP and beat-to-beat CO monitoring with pulse waveform analysis and transthoracic bioimpedance changes during spinal anesthesia for CD in 40 healthy parturients and demonstrated similar results [21] . After induction of SA, there was a 36 % decrease in SVR and a 25 % compensatory increase in CO because of increases in both HR and stroke volume (SV) [13 • , 21] . These studies both suggest that the fall in SVR seen with SA results in partial compensatory increases in CO brought about by increases in HR with or without an associated increase in SV.
A less frequent response to SA is bradycardia and a fall in CO associated with hypotension. This reflex effect is known as the supine hypotensive syndrome of pregnancy [15, 22, 23] , and is believed to occur as a result of vena caval obstruction or vagal reflex bradycardia associated with an inadequately filled heart, and may involve the Bezold-Jarisch reflex [15, 24, 25] . As the block height rises, reflex inhibition of the vagus nerve results in sympathectomy and bradycardia [25] .
Fetal Effects of Spinal Hypotension
Animal studies under normal physiological conditions have shown that uteroplacental blood flow exceeds the oxygen requirement of fetal oxygen demand, providing a safety margin in terms of uterine flow fluctuations [16 • , 26] . As a result, the effect of reduced utero-placental perfusion on the fetus is debatable. Maayan-Metzger et al. [27] of 919 term singleton pregnancies undergoing elective CD under SA, showed that maternal hypotension of more than 30 and 50 % from baseline did not correlate with any perinatal complications.
In a large epidemiological study by Laudenbach et al., however, SA was found to be associated with an increased risk of perinatal mortality in very preterm infants of 27-32 weeks' gestation. The study included all births occurring before 33 weeks gestation, and compared fetal outcomes for those delivered by CD under general anesthesia (GA) or spinal or epidural anesthesia. SA was associated with an increased risk of neonatal mortality in very preterm infants, compared with the GA and epidural groups [28] . However, this was an epidemiological study, with no information regarding strategies for hemodynamic control or vasopressor use, so one should be careful about inferring conclusions from this study.
Vasopressor Effects on Maternal Pathophysiology
To prevent unpleasant symptoms in the mother, and for the safety of both the mother and fetus, the hemodynamic changes associated with SA for CD should be treated or, better still, prevented. Use of vasopressors has become routine practice in the management of spinal hypotension. The ideal vasopressor, or combination of vasopressors, used would compensate for the progressive effects of ascending sympathetic blockade, maintain maternal cardiovascular stability, prevent nausea and vomiting, and have no adverse effects on uteroplacental blood flow or the fetus. Ephedrine (an alpha and beta adrenergic receptor agonist) was widely used for many years, because the alpha-adrenergic agonist effects of PE were thought to reduce uteroplacental blood flow by increasing SVR, with potentially deleterious effects for the fetus [29 • , 30] . Recent research using minimally invasive or non-invasive CO measurement techniques on pregnant women has enabled us to determine the hemodynamic effects of vasopressors in more detail. As a result of this work, it is now widely accepted that the vasopressor of choice in the parturient is PE [10 • , 31-34] . Vasopressors, however, have general systemic effects with potential adverse effects on other organs and the fetus. Their use and dosing should be carefully adjusted to avoid these adverse effects while maintaining maternal hemodynamic stability.
Phenylephrine
As already discussed, spinal hypotension during elective CD is associated with a reduction in SVR and a compensatory increase in CO mediated by an increase in HR and stroke volume. On the basis of this pathophysiological mechanism, PE, a rapidly acting alpha-adrenergic agonist, would seem to be the vasopressor of choice because it counteracts the drop in SVR and thereby restores baseline hemodynamics. Low doses of PE increase VR and CO, by causing an increase in splanchnic venous tone, in term parturients with an expanded blood volume [16 • , 35] . Higher doses of PE, however, cause a baroreceptor-mediated drop in HR, dilatation of the splanchnic circulation, diversion of blood to the splanchnic vessels, and a decrease in VR [36] . This would suggest that PE may be more effective and beneficial when used as a low-dose infusion, rather than as a bolus. Allen et al. recently studied four fixed-rate infusion regimens of PE for hemodynamic support during SA for CD. PE 25 and 50 lg/min administered as a prophylactic fixed rate infusion provided greater maternal hemodynamic stability than PE 75 and 100 lg/min [37] .
Stewart et al. performed a randomized double-blind study of 75 women undergoing elective CD under SA in our institution, investigating the dose-dependent effects of PE. Patients were randomly allocated to receive one of three PE infusion regimens, 25, 50, or 100 lg/min, titrated to maintain their SBP at or above 80 % of baseline. We showed that higher doses of PE (50 and 100 lg/min) are associated with significant dose-dependent reductions in both maternal HR and CO [10 • ]. These findings are in keeping with previous studies by Langesaeter et al. [20] and Dyer et al. [21] , which also found a reduction in CO with PE infusion. The study performed by Langesaeter et al. [20] questioned the routine use of higher doses of PE. In an attempt to maintain BP at baseline levels, PE may also reduce CO by reducing stroke volume, in response to an increase in SVR. This effect is demonstrable after bolus administration of PE [21] and was not demonstrated when using PE in the form of an infusion [10 • ].
Robson et al. [38] suggested that CO, rather than BP, correlated more closely with uteroplacental blood flow. Uterine blood flow, and hence oxygen supply to the fetus, is dependent on maternal CO. As the fetus has little oxygen-storage capacity and is completely dependent on placental oxygen delivery, the well-being of the fetus requires maternal CO, uterine blood flow, and maternal PaO 2 to be maintained at or above normal values for pregnancy [10 • , 39] . Stewart et al. showed that, despite the decrease in CO associated with the use of higher doses of PE, no adverse effects were observed in the fetus, as indicated by Apgar scores and by umbilical arterial and venous blood gases [10 • ]. However, the study by Laudenbach et al., discussed above, clearly demonstrated an increased risk of neonatal mortality for very preterm infants associated with SA. This finding raises the question as to whether this small decrease in CO may have a detrimental effect on vulnerable, preterm, or high-risk fetuses. Therefore when performing SA for CD, fetal oxygen delivery should be optimized, by maintaining maternal CO and BP at or as near to baseline as possible.
Ephedrine
Ephedrine (E), a mixed alpha and beta adrenoreceptor agonist, was previously the vasopressor of choice for treatment of spinal hypotension. Ephedrine has a more delayed pressor effect than PE, and increases both maternal HR and CO [21] . During SA it is usually not necessary to increase CO, because there is already a compensatory increase in response to the dramatic drop in SVR [20, 21] . The delay in the pressor effects of ephedrine results in an increased incidence of maternal nausea and vomiting.
A recent editorial by Dyer and Biccard [25] discussed fetal considerations associated with use of ephedrine. Ephedrine has been shown to cross the placenta and to increase base deficit in the fetus by increasing the fetal metabolic rate [31] . Although the acidosis related to ephedrine use has not been associated with hypoxia or adverse fetal outcome, Dyer and Biccard contend that in an already compromised fetus the oxygen supply/demand ratio may be adversely affected. Furthermore, Ngan Kee et al. [40] found that ephedrine use during elective CD was associated with higher lactate and plasma catecholamine concentrations, lower umbilical arterial pH, and a greater base deficit in the fetus compared with PE. It should be noted that the higher doses of ephedrine used in this study, and the different dosing regimens, may be associated with varying degrees of fetal acidosis.
A previous study by the same group demonstrated that during emergency CD there were no significant differences in pH and base deficit between the use of ephedrine and PE, although umbilical cord lactate levels were found to be significantly higher after ephedrine use [41] . A more recent study by Landau et al. found that not all neonates developed acidosis when ephedrine was used, and that the effect depended on their genetic make-up. They suggested that some neonates are more sensitive to the effects of ephedrine, because of differences in their adrenaline beta-2 receptor genotype. This would imply that even small doses of ephedrine, used to treat spinal hypotension, could result in significant neonatal acidosis in genetically susceptible fetuses [42] .
Overall, there is good evidence of both fetal and maternal well-being after use of alpha adrenoreceptor agonists, for example PE, as first-line vasopressors to maintain maternal hemodynamic stability during SA for CD [25, 43 • ] . PE infusions are associated with lower fetal base deficit than ephedrine infusions [44] , because flow in the vasodilated uteroplacental circulation is systemic pressure-dependent and the uterine artery is relatively insensitive to alpha agonists [25] . So from a fetal perspective PE is associated with a higher pH and lower base deficit. From a maternal perspective it is associated with a rapid rise in SVR and restoration of HR, CO, and BP to baseline levels.
Methods of CO Monitoring
In daily practice, we use maternal vital signs as a surrogate for CO estimation. Traditionally, BP has been believed to be the most important variable to maintain as close to baseline as possible during CD under SA. Recent research studies, however, have revealed that HR may be a better surrogate marker for CO estimation. Continuous measurement of CO is not performed routinely during CD, but should be considered in the management of high-risk parturients. In the awake pregnant population, CO measurement is usually in the form of non-invasive or minimally invasive techniques. When CO monitoring is not indicated, SBP should be maintained at or near to baseline by lowdose PE infusion, and HR should be used as a surrogate marker for maternal CO. Significant reductions in maternal HR may not be clinically as important in cases when there is a term healthy fetus, but should be promptly treated in situations when there is a preterm or compromised fetus.
Armstrong et al. [45 • ] provides a more in depth description of all non-invasive and minimally invasive methods of CO monitoring. A brief outline of the techniques currently available is given below (Tables 1, 2, 3 ).
Non-invasive Techniques
These techniques are based on Doppler velocimetry using ultrasound of aortic blood flow or on measurement of electrical resistance changes induced by vascular flow [45 • ].
Transthoracic and Transesophageal Echocardiography
Transthoracic (TTE) and transesophageal echocardiography (TEE) enable assessment of hemodynamic variables and cardiac structures; they can also be used to measure valvular and ventricular wall thickness and detect wall motion abnormalities. Use of TEE for diagnosis and management of high-risk cardiac conditions in pregnancy, including cardiomyopathy, and pulmonary and amniotic fluid embolism, has been well described; however, it requires deep sedation or general anesthesia, and is therefore not clinically applicable for the awake parturient [45 • , 46-51] . Because TTE is non-invasive, feasible for an awake parturient, and useful for different diagnostic conditions and for assessing response to treatment, the popularity of TTE in obstetric anesthesia is increasing. Dennis et al. [52] , have described the rapid obstetric screening Curr Anesthesiol Rep (2013) 3:282-291 285 echocardiography (ROSE) scan, and its application in the clinical setting. The ROSE scan enables rapid and focused TTE examination in the setting of unpredictable and lifethreatening obstetric emergencies. It is an acceptable and applicable bedside test, performed in the left lateral position, enabling comfortable and concise examination in the emergency setting. Parasternal and apical maternal cardiac views are obtained to assess contractility and volume status, aiding diagnosis and response to therapy. Right heart function and relative size are also assessed, which are particularly helpful if embolism is suspected. It also provides rapid fetal heart assessment. These abbreviated techniques can be taught to, and practiced by, clinicians, although they do not replace the formal qualitative TTE that can be performed electively at a later stage [52] .
Doppler Velocimetry
This method uses the Doppler frequency shift produced as an ultrasound beam is reflected by moving red cells. This frequency shift is proportional to the blood flow velocity. Doppler ultrasound measurements of ascending aortic blood velocity have been shown to enable accurate noninvasive measurement of CO, which has been validated in pregnancy [44, [53] [54] [55] . Doppler velocimetry can be used for CO measurement in the form of transesophageal or suprasternal aortic Doppler velocimetry.
Transthoracic and Whole-Body Electrical Bioimpedance
Bioimpedance techniques detect electrical resistances across the thorax or whole body, induced by vascular flow during the cardiac cycle. CO is continuously estimated from signal variations. Bioimpedance, however, is affected by other factors, including pulmonary edema, patient position, and diathermy rendering it impractical for use in patients undergoing CD. There are currently few data supporting the reliability of these devices for the pregnant population [45 • , 56] .
Bioreactance and Electrical Velocimetry
This technique was developed in an attempt to overcome the problems associated with bioimpedance. Bioreactance and electrical velocimetry involve the analysis of phase shifts of an oscillating current as it traverses the thorax. Few publications exist on the use of these methods for parturients, and so further research is required before its routine use can be recommended [45 • , 57, 58] . Doherty et al. assessed hemodynamic changes during elective CD under SA by use of a non-invasive CO monitor based on bioreactance. They found that, despite maintaining maternal BP at baseline with PE boluses, bioreactance revealed significant hemodynamic fluctuations [58] . A recent study comparing the two methods for 25 awake patients after coronary artery bypass graft surgery found a close correlation between Nexfin CO-trek measurements of CO and thermodilution methods of CO measurement, whereas Modelflow readings varied significantly [60] .
Minimally Invasive Techniques
Minimally invasive CO measurement methods include pulsecontour waveform analysis and pulse-dye densitometry.
Pulse Contour Waveform Analysis
This method uses the arterial waveform derived from an invasive arterial line to predict vascular flow. The two commonly used devices are the LiDCO and PiCCO systems. The LiDCO system is based on the lithium dilution method whereas the PiCCO system is based on transpulmonary thermodilution. These methods provide continuous real time data and the algorithms used are precise and reliable in following changes in CO [45 • , 61] . Pulse contour studies have been well studied and validated [62] [63] [64] . Two LiDCO systems currently in clinical use: the LiDCOplus system runs two proprietary algorithms: a continuous arterial waveform analysis system (PulseCO) coupled to a single point lithium indicator dilution calibration system (LiDCO). PulseCO uses an algorithm based on patient height, weight, gender, and age to estimate arterial compliance. The PulseCO algorithm derives SV from arterial pressure changes over time.
The LiDCOrapid system uses the PulseCO algorithm to derive SV and HR from the BP waveform. The algorithm converts BP to volume, to account for aortic compliance and capacitance. Although the Flo Trac-Vigileo is the newest of the arterial pulse contour devices, it has been extensively investigated and validated in more than 20 studies [45 • , 56] . It uses statistical analysis of 20-s windows of radial artery pressure waveforms together with estimates for compliance; it also incorporates patient demographics into its calculations [59] . Compared with other methods this device has the limitation that it does not provide continuous real-time data; it does, however, have the advantage that it has self-calibrating software. Therefore, this method of measurement may not be suitable for the rapid hemodynamic fluctuations that occur during CD or major obstetric hemorrhage, because of concerns regarding its reliability during changes in peripheral vascular resistance [65] .
Pulsed Dye Densitometry
This technique enables intermittent CO measurement on the basis of transpulmonary dye dilution using transcutaneous signal detection adapted from pulse oximetry [45 • ]. CO is calculated from the dye-dilution curve. The technique is subject to interference from several sources, including vasoconstriction and interstitial edema. As a result, validation techniques have revealed only moderate agreement with thermodilution techniques [45 • , 66, 67] . In addition, because of concerns about the effects of maternal administration of indocyanine green dye on the fetus, this method cannot currently be recommended for use in obstetric practice.
Conclusion
SA is the most widely used method of anesthesia for CD. The typical response to SA for CD is hypotension and an increase in maternal HR. Recent research using minimally invasive and non-invasive CO monitoring has shown that these changes are a result of the dramatic decrease in SVR seen with SA and a compensatory increase in CO. As a result, we are now in a better position to target our management of spinal hypotension. However, use of these CO-monitoring techniques is the exception rather than routine and may be best suited to particularly high-risk parturients. CO outputmonitoring devices need further formal validation before their use in pregnancy can be recommended.
Maternal positioning to reduce aortocaval compression and fluid co-hydration continues to be routine practice, but has not been shown to be sufficient to prevent or relieve spinal hypotension. This is because spinal hypotension is N number studied, BP blood pressure, VP vasopressor, PE phenylephrine, E ephedrine, LR lactated Ringer's, SBP systolic blood pressure, CO cardiac output, HR heart rate, Bup bupivacaine, fent fentanyl, SA spinal anesthesia, SVR systemic vascular resistance not purely a consequence of reduction in VR, as previously believed. Without prophylactic management or timely treatment, more than 80 % of parturients will develop spinal hypotension, leading to unpleasant maternal effects, for example nausea and vomiting and, in more severe cases, cardiovascular collapse, unconsciousness, and aspiration of gastric contents. Spinal hypotension reduces uteroplacental blood flow, and this may have an adverse effect on fetal well-being, particularly if the fetus is preterm or already compromised. Spinal hypotension should therefore be prevented, and treated as soon as it occurs. Increasing evidence suggests the most appropriate firstline vasopressor for treatment of spinal hypotension is an alpha adrenoreceptor agonist, for example PE, which rapidly increases SVR and restores BP to baseline. It has become routine practice to use PE prophylactically as an infusion; however, care should be taken to avoid maternal sinus bradycardia, because this is likely to be indicative of a clinically significant decrease in CO. Recent research supports the view that HR, rather than BP, as originally believed, should be used as a surrogate marker for CO.
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